Lozapine

/ Taro

Schizophrenia, only in cases non-responsive to conventional therapy.

Patients with a history of drug-induced granulo-cytopenia/agranuloxytosis, or with bone marrow disorder should not be treated with this drug. Alcoholic and other toxic psychoses, drug intoxication, comatose conditions, severe hepatic, renal or cardiac disease and uncontrolled epilepsy. Not to be used concurrently with drugs associated with a substantial potential for causing agranulocytosis. The concomitant use of long acting depot antispychotics should be avoided. Before starting treatment a white blood count (WBC) and differential blood count must be performed. WBC count must be monitored weekly for 18 weeks and then monthly as long as treatment is given.
See prescribing information for full details.

To be dispensed only upon psychiatrist’s prescription. Because of the significant risk of agranulocytosis, Lozapine should be reserved for use in the treatment of severely ill schizophrenic patients who fail to show an acceptable response to adquate courses of standard drug treatment for schizophrenia.
See prescribing information for full details.

Hyperglycemia, impairment of intestinal peristalsis. Drowsiness/sedation, dizziness/vertigo, headache and tremor, salivation, sweating, dry mouth and visual disturbances, cardiovascular findings, constipation and nausea, fever.
See prescribing information for full details.

Alcohol, CNS depressants, cimetidine, disulfiram, carbamazepine, levodopa. Antihypertensives, anticholinergics. Co-trimoxazole, chloramphenicol, sulphonamides, pyrazolone analgesics, phenylbutazone, penicillamine, cytotoxic agents, carbamazepine, depot antipsychotics. Lithium, warafarin, other plasma protein bound drugs. Adrenaline, alpha agonists, cimetidine, phenytoin, carbamazepine, fluvoxamine.